Day: October 24, 2022

Posted on

Taconic Biosciences Launches First and Only Super Immunodeficient Mouse Models Lacking Residual Murine Fc Gamma Receptors, for Improved Antibody Therapy Assessment

FcResolv™ NOG Models Provide Greater Clarity and More Translatable Data

RENSSELAER, N.Y., Oct. 24, 2022 (GLOBE NEWSWIRE) — Taconic Biosciences, a global leader in providing drug discovery animal model solutions, has launched the FcResolv™ NOG portfolio, the first and only super immunodeficient mouse models lacking residual murine Fc gamma receptors (FcγRs) known to confound results in antibody-based therapy studies.

Murine FcγRs can cause false positives or false negatives, leading to incorrect conclusions and derail drug discovery. FcResolv NOG models knock out these receptors for greater clarity in antibody-based drug studies, affording investigators greater confidence and more translatable data with fewer studies and fewer animals. With applicability in oncology, immuno-oncology, and autoimmune disease, FcResolv NOG models are suitable for engrafting a wide range of human cells and tissues, including simultaneous human tumor engraftment and immune system humanization.

“Antibody-based therapies represent one of the fastest-growing classes of drugs, creating a pressing need for better preclinical tools to assess therapeutics such as monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies,” said Dr. Michael Seiler, vice president of commercial products at Taconic. “Taconic’s FcResolv NOG portfolio enables researchers to evaluate drug candidates like these on their own merits, free of interference from residual murine Fc gamma receptor activity.”

FcResolv NOG models eliminate the false negatives that occur when an antibody-based therapeutic’s Fc domain interacts with murine FcγRs as well as the false positives that result when FcγRs trigger residual murine immune activity. They also eliminate costly deconvolution steps otherwise needed to distinguish true drug efficacy from off-target effects mediated through the mouse immune system. With more reliable answers, researchers can target their drug discovery investments more strategically and effectively.

The FcResolv NOG model portfolio is based on the super immunodeficient CIEA NOG mouse®. The portfolio currently includes two models:

  • FcResolv NOG, for tumor xenografts using cell lines or patient-derived tumors, engraftment of other normal or pathological human cells and tissues, and immune system humanization studies
  • FcResolv hIL-15 NOG, which supports engraftment of human NK cells and is suitable for efficacy studies on antibody-based therapeutics with an antibody-dependent cellular cytotoxicity (ADCC) mechanism of action

To learn more about the FcResolv NOG portfolio, visit www.Taconic.com/fcresolv. Or call 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe, or email info@taconic.com.

About Taconic Biosciences, Inc.

Taconic Biosciences is a fully licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom-generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, microbiome, immuno-oncology mouse models, and integrated model design and breeding services, Taconic operates service laboratories and breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.

Media Contact:

Louise Baskin, Senior Director New Product Pipeline

303-432-2495

Louise.Baskin@taconic.com

GlobeNewswire Distribution ID 8670208

Posted on

Taconic Biosciences lance le premier et le seul modèle de souris super immunodéficientes dépourvus de récepteurs Fc Gamma murins résiduels, pour une évaluation améliorée de la thérapie par anticorps

Les modèles FcResolv™ NOG offrent une plus grande clarté et des données plus traduisibles

RENSSELAER, New York, 24 oct. 2022 (GLOBE NEWSWIRE) — Taconic Biosciences, un leader mondial dans la fourniture de solutions de modèles animaux pour la découverte de médicaments, a lancé le portefeuille FcResolv™ NOG, les premiers et seuls modèles de souris super immunodéficientes dépourvus de récepteurs Fc Gamma murins résiduels (FcyRs) connus pour fausser les résultats dans les études thérapeutiques à base d’anticorps.

Les FcyRs murins peuvent provoquer de faux positifs ou de faux négatifs, ce qui conduit à des conclusions erronées et fait dérailler la découverte de médicaments. Les modèles FcResolv NOG éliminent ces récepteurs pour une plus grande clarté dans les études médicamenteuses à base d’anticorps, offrant aux chercheurs une plus grande confiance et des données plus traduisibles avec moins d’études et moins d’animaux. Avec une applicabilité en oncologie, en immuno-oncologie et en maladie auto-immune, les modèles FcResolv NOG sont adaptés à la greffe d’un large éventail de cellules et tissus humains, y compris la greffe de tumeurs humaines simultanée et l’humanisation du système immunitaire.

« Les thérapies à base d’anticorps représentent l’une des classes de médicaments à la croissance la plus rapide, créant un besoin urgent de meilleurs outils précliniques pour évaluer des traitements tels que les anticorps monoclonaux, les conjugués anticorps-médicaments et les anticorps bispécifiques », a déclaré le Dr Michael Seiler, vice-président des produits commerciaux chez Taconic. « Le portefeuille de récepteurs FcResolv NOG de Taconic permet aux chercheurs d’évaluer des médicaments candidats tels que ceux-ci selon leurs propres mérites, sans interférence de l’activité résiduelle du récepteur Fc Gamma murin. »

Les modèles FcResolv NOG éliminent les faux négatifs qui se produisent lorsqu’un domaine Fc thérapeutique à base d’anticorps interagit avec les FcyRs murins, ainsi que les faux positifs qui en résultent lorsque les FcyRs déclenchent une activité immunitaire murine résiduelle. Ils éliminent également les étapes de déconvolution coûteuses nécessaires pour distinguer une véritable efficacité médicamenteuse des effets hors cible induits par le système immunitaire de la souris. Grâce à des réponses plus fiables, les chercheurs peuvent cibler leurs investissements dans la découverte de médicaments de manière plus stratégique et plus efficace.

Le portefeuille de modèles NOG FcResolv est basé sur la souris® NOG CIEA super immunodéficiente. Le portefeuille comprend actuellement deux modèles :

  • FcResolv NOG, pour les xérogreffes tumorales utilisant des lignées cellulaires ou des tumeurs dérivées des patients, la greffe d’autres cellules et tissus humains normaux ou pathologiques, et les études d’humanisation du système immunitaire
  • FcResolv hIL-15 NOG, qui supporte la greffe des cellules NK humaines et convient pour des études d’efficacité sur les thérapies à base d’anticorps avec un mécanisme d’action de cytotoxicité cellulaire dépendant des anticorps (ADCC)

Pour en savoir plus sur le portefeuille de FcResolv NOG, rendez-vous sur www.Taconic.com/fcresolv. Vous pouvez également appeler le 1-888-TACONIC (888-822-6642) aux États-Unis, le +45 70 23 04 05 en Europe, ou envoyer un e-mail à l’adresse info@taconic.com.

À propos de Taconic Biosciences, Inc.

Taconic Biosciences est un leader mondial pleinement agréé dans les modèles et les services de rongeurs génétiquement modifiés. Fondée en 1952, Taconic offre les meilleures solutions animales afin que les clients puissent acquérir, générer d’une manière personnalisée, élever, pré-conditionner, tester et distribuer des modèles de recherche précieux dans le monde entier. Spécialiste des modèles de souris et de rats génétiquement modifiés, du microbiome, des modèles de souris pour l’immuno-oncologie et des services de conception de modèles intégrés et d’élevage, Taconic exploite des laboratoires de services et des établissements d’élevage aux États-Unis et en Europe, entretient des relations de distribution en Asie et dispose de capacités d’expédition mondiales pour fournir des modèles animaux presque partout dans le monde.

Contact auprès des médias :

Louise Baskin, directrice principale du nouveau Pipeline de produits

303-432-2495

Louise.Baskin@taconic.com

GlobeNewswire Distribution ID 8670426


Posted on

Taconic Biosciences Lança Primeiro e Único Modelo de Camundongo Super Imunodeficiente Sem Receptores Gama Fc Murino Residuais, para Avaliação de Terapia de Anticorpo Aprimorada

Modelos FcResolv™ NOG proporcionam dados mais claros e mais traduzíveis

RENSSELAER, NY, Oct. 24, 2022 (GLOBE NEWSWIRE) — A Taconic Biosciences, líder global no fornecimento de soluções de modelo animal para descoberta de medicamentos, lançou o portfólio FcResolv™ NOG, o primeiro e único modelo de camundongo superimunodeficiente sem receptores Fc gama murinos residuais (FcγRs) conhecidos por confundir os resultados nos estudos de terapia com base em anticorpos.

Os FcγRs murinos podem causar falsos positivos ou falsos negativos, levando a conclusões incorretas e afetar a descoberta de medicamentos. Os modelos FcResolv NOG eliminam esses receptores para maior clareza nos estudos de medicamentos com base em anticorpos, proporcionando aos investigadores maior confiança e dados mais traduzíveis, com menos estudos e menos animais. Com aplicabilidade em oncologia, imuno-oncologia e doença autoimune, os modelos FcResolv NOG são adequados para enxertos de uma ampla gama de células e tecidos humanos, incluindo enxerto simultâneo de tumor humano e humanização do sistema imunológico.

“As terapias com base em anticorpos são uma das classes de medicamentos de crescimento mais rápido, criando uma necessidade urgente de melhores ferramentas pré-clínicas para a avaliação terapêutica, como de anticorpos monoclonais, conjugados anticorpo-droga e anticorpos biespecíficos”, disse o Dr. Michael Seiler, vice-presidente de produtos comerciais da Taconic. “O portfólio FcResolv NOG da Taconic permite que pesquisadores avaliem candidatos a medicamentos como esses por si próprios, sem interferência da atividade residual do receptor Fc gama murino.”

Os modelos FcResolv NOG eliminam os falsos negativos que ocorrem quando o domínio Fc de um terapêutico com base em anticorpos interage com os FcγRs murinos, bem como os falsos positivos que resultam quando os FcγRs desencadeiam atividade imune murina residual. Eles também eliminam as etapas dispendiosas de desconvolução que normalmente são necessárias para distinguir a verdadeira eficácia do medicamento dos efeitos fora do alvo mediados pelo sistema imunológico do camundongo. Com respostas mais confiáveis, os pesquisadores podem direcionar seus investimentos em descoberta de medicamentos de forma mais estratégica e eficaz.

O portfólio do modelo FcResolv NOG tem como base o CIEA NOG mouse® superimunodeficiente. Atualmente, o portfólio inclui dois modelos:

  • FcResolv NOG, para xenoenxertos de tumores com linhagens celulares ou tumores derivados de pacientes, enxerto de outras células e tecidos humanos normais ou patológicos, e estudos de humanização do sistema imunológico
  • FcResolv hIL-15 NOG, que aceita enxertos de células NK humanas e é adequado para estudos de eficácia em terapêutica com base em anticorpos com um mecanismo de ação de citotoxicidade celular dependente de anticorpos (ADCC)

Para mais informação sobre o portfólio FcResolv NOG, visite www.Taconic.com/fcresolv. Ou ligue para 1-888-TACONIC (888-822-6642) nos EUA, +45 70 23 04 05 na Europa, ou envie email para info@taconic.com.

Sobre a Taconic Biosciences, Inc.

A Taconic Biosciences é uma líder global totalmente licenciada em serviços e modelos geneticamente modificados. Fundada em 1952, a Taconic oferece as melhores soluções/modelos de pesquisas em murinos, para que os clientes possam adquirir, customizar, criar, pré-condicionar, testar e distribuir valiosos modelos de pesquisa em todo o mundo. Especializada em modelos de camundongos e de ratos geneticamente projetados, microbioma, modelos de camundongos imuno-oncologia, e serviços de design e criação de modelos integrados, a Taconic opera laboratórios de serviços e instalações de criação nos EUA e na Europa, mantém relações com distribuidores na Ásia , e tem capacidades de entrega em nível global para oferecer modelos em quase qualquer lugar no mundo.

Contato com a Mídia:

Louise Baskin, Diretora Sênior de Pipeline de Novos Produtos

303-432-2495

Louise.Baskin@taconic.com

GlobeNewswire Distribution ID 8670426

Posted on

WFP at COP 27: Climate adaptation solutions needed to halt global food crisis

ROME – As world leaders gather at the UN Climate Change Conference (COP27) in Egypt next month, WFP highlights the urgent need for climate adaptation solutions to stem the tide of growing hunger. The unfolding global food crisis cannot be stopped until we support communities and nations to manage the risks associated with a changing climate.

Extreme climate impacts like droughts, heatwaves and floods are one of the leading causes of hunger destroying crops and agricultural land, decimating livelihoods and wreaking havoc in already vulnerable communities. A shocking 40 percent of the global population lives in areas that are already highly vulnerable to climate extremes.

At COP27, WFP is showcasing solutions to avert and minimize loss and damage in vulnerable livelihoods and food systems. WFP is also calling for increased investment in climate adaptation for communities in fragile contexts, and the transformation of global food systems towards greener, more equitable and resilient pathways.

WFP is making available to the media experts at COP27 who can comment on the changing climate, its impact on food security and WFP solutions:

Gernot Laganda – WFP Director of Climate and Disaster Risk Reduction
Martin Frick – Climate and Food Systems Expert and Director of the WFP Berlin Office
Corinne Fleischer – WFP Regional Director for Middle East and North Africa
Menghestab Haile – WFP Regional Director for Southern Africa
Mathieu Dubreuil – WFP Climate Insurance Expert
Elizabeth Nyamayaro – WFP Special Advisor
(Other experts available on request)
**WFP is also pleased to invite media to a press conference **on Saturday 12 November at 11:30am at the press conference room ‘Cairo’ in the Nefertiti Area. For registrations contact: jenny.wilson@wfp.org; +39 342 123 5169

WFP will be present at the following sessions at COP 27.

The Climate Emergency is a Hunger Emergency, UNFCCC Pavilion, 8 November, 2pm
Environmentally Sustainable Solutions to Climate Change – Impact on vulnerable communities in Egypt and other African countries, UN in Egypt Pavilion, 9 November, 5pm
Climate-resilient food systems and peace: Exploring the interconnections, Room 8, 11 November 1:15pm
Turning Ambition into Action through the Power of Partnerships: Scaling up Anticipatory Action, UAE Pavillion, 12 November 10am
Disrupt Hunger | Innovating For People And Planet, UNFCCC Pavilion, 17 November 4pm
Join us on Twitter Spaces @WFP:

25 October, 10am – Loss and Damage: Solutions for communities on the frontlines
31 October, 11am – Anticipatory Action: First-hand accounts
**Examples of WFP’s work from the forefront of climate and hunger – **video footage here, photos here.

Source: World Food Programme

Posted on

More than half of world’s unregistered children under 5 in Africa – UNICEF

ADDIS ABABA, 24 October 2022 — Of the 164 million unregistered children under 5 worldwide, more than half (around 91 million) live in Africa, according to a new statistical update on birth registration in Africa, published by UNICEF in partnership with the UN Economic Commission for Africa (UNECA).

Nearly half of all African children under 5 are unregistered, but levels vary widely across countries and regions.

Around 20 countries on the continent are on a good track to achieve universal birth registration by 2030 in line with the Sustainable Development Goals (SDG) target 16.9. However, substantial acceleration would be needed for Africa as a whole to achieve the target.

“A birth certificate is a vital tool to help children access their rights. It is the basis upon which they can establish a nationality, avoid the risk of statelessness, access social services and seek protection from violence and exploitation,” said Mohamed Malick Fall, UNICEF Regional Director for Eastern and Southern Africa.

The poorest children in Africa continue to be left behind, with the gap in birth registration between the richest and poorest children widening over two decades, most notably in Central Africa. With sustained progress, Africa could continue to see fewer unregistered children in the years to come.

“Evidence from UNICEF-supported programmes across the continent points to a few critical interventions that could shift the needle towards ensuring every child’s right to birth registration, as enshrined in the Convention on the Rights of the Child,” said Marie-Pierre Poirier, UNICEF Regional Director for West and Central Africa. “By twinning birth registration with newborn health and immunisation services, making sure all children who are in contact with these services during their first year of life are also registered, countries could see birth registration rates increase dramatically.”

The new statistical update is being launched during African Union Commission and UNECA hosted Experts Group Meeting of the 6th Conference of African Ministers Responsible for Civil Registration in Addis Ababa, Ethiopia from 24-27 October 2022.

Legal identity for all in Africa — starting from birth — could be a game-changer in closing the global identity gap and fulfilling the promise to leave no one behind. UNICEF is calling on African Union member states to:

Revise laws and policies to remove all discriminatory provisions and make registration and certification free within the legally permissible time period and beyond.
Adopt a one-stop approach for newborn registration and certification that is entirely interoperable with health and immunisation systems, including in humanitarian contexts.
Take a gradual approach to digitization of systems, while adhering to safe and innovative practices, based on a holistic approach to ensure the universal civil registration of all vital events and identity management
The Sustainable Development Goals, adopted in 2015, include a dedicated target (16.9) under Goal 16 — namely, to provide legal identity for all, including birth registration, by 2030. The UN Legal Identity Agenda, supported by UNICEF, also calls for a holistic approach to ensure the universal civil registration of all vital events, production of vital statistics, and the establishment and maintenance of population registers and identity management apparatus from birth to death.

Since the adoption of the SDGs, great strides have been made in raising the levels of birth registration in Africa, but a substantial acceleration of progress will be required to fulfil the promise of universal birth registration by 2030.

Source: UN Children’s Fund